| Oct 31 |
I-Mab to Release Q3 2024 Financial Results on November 14, 2024
|
| Oct 30 |
I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024
|
| Oct 28 |
I-Mab to Participate at the Truist Securities BioPharma Symposium
|
| Oct 25 |
I-Mab Biopharma’s Strategic US Transition and Pipeline Focus
|
| Oct 9 |
IMab (IMAB) Moves to Buy: Rationale Behind the Upgrade
|
| Sep 16 |
I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024
|
| Sep 10 |
I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer
|
| Aug 30 |
I-Mab First Half 2024 Earnings: US$0.19 loss per share (vs US$1.32 loss in 1H 2023)
|
| Aug 28 |
I-MAB (IMAB) Q2 2024 Earnings Call Transcript
|
| Aug 28 |
I-Mab Biopharma GAAP EPADS of -$0.09 beats by $0.13
|
